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Abstract
Introduction: A deletion polymorphism in glutathione S-transferase Mu-1 (GSTM1-null) has previously been
implicated to play a role in rheumatoid arthritis (RA) risk and progression, although no prior investigations have
examined its associations with anticitrullinated protein antibody (ACPA) positivity. The purpose of this study was to
examine the associations of GSTM1-null with ACPA positivity in RA and to assess for evidence of interaction
between GSTM1 and HLA-DRB1 shared epitope (SE).
Methods: Associations of GSTM1-null with ACPA positivity were examined separately in two RA cohorts, the
Veterans Affairs Rheumatoid Arthritis (VARA) registry (n = 703) and the Study of New-Onset RA (SONORA; n = 610).
Interactions were examined by calculating an attributable proportion (AP) due to interaction.
Results: A majority of patients in the VARA registry (76%) and SONORA (69%) were positive for ACPA with a similar
frequency of GSTM1-null (53% and 52%, respectively) and HLA-DRB1 SE positivity (76% and 71%, respectively). The
parameter of patients who had ever smoked was more common in the VARA registry (80%) than in SONORA
(65%). GSTM1-null was significantly associated with ACPA positivity in the VARA registry (odds ratio (OR), 1.45; 95%
confidence interval (CI), 1.02 to 2.05), but not in SONORA (OR, 1.00; 95% CI, 0.71 to 1.42). There were significant
additive interactions between GSTM1 and HLA-DRB1 SE in the VARA registry (AP, 0.49; 95% CI, 0.21 to 0.77; P <
0.001) in ACPA positivity, an interaction replicated in SONORA (AP, 0.38; 95% CI, 0.00 to 0.76; P = 0.050).
Conclusions: This study is the first to show that the GSTM1-null genotype, a common genetic variant, exerts
significant additive interaction with HLA-DRB1 SE on the risk of ACPA positivity in RA. Since GSTM1 has known
antioxidant functions, these data suggest that oxidative stress may be important in the development of RA-specific
autoimmunity in genetically susceptible individuals.
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The human leukocyte antigen (HLA) region accounts for
approximately one half of the genetic risk of rheumatoid
arthritis (RA). This risk is attributable to alleles encod-
ing a conserved amino acid sequence in the third hyper-
variable region of the DRB1 chain (commonly referred
to as the shared epitope [SE]) [1]. Recent efforts have
examined the importance of interactions of SE with
other genetic and environmental factors in RA risk and
progression. Most notably, studies have yielded evidence
of significant interactions between SE and cigarette
smoking in the development of anticitrullinated protein
antibody (ACPA)-positive RA [2,3], although the precise
mechanisms underpinning this interaction are not
understood.
Genetic and environmental factors that mediate oxida-
tive stress, including cigarette smoking, are postulated to
play a central role in the pathogenesis of autoimmune
disorders including RA. While oxidative stress represents
a form of host defense, it can also result in tissue damage.
Oxidative modification of proteins and other biologic
molecules leads to the expression of neoantigens, a possi-
ble first step in the development of autoimmunity, which
may herald the future onset of clinically relevant autoim-
mune disease [4]. Antioxidants, which mitigate tissue
damage caused by reactive oxygen species, may serve
important protective functions in RA. While not all stu-
dies have identified a similar protective effect [4,5], the
dietary intake of small-molecule antioxidants has been
reported to be inversely associated with RA risk [6-9].
Additionally, low circulating levels of antioxidants have
been reported to portend the onset of RA [10].
In addition to the effects of exogenous antioxidants,
oxidation is also regulated by several enzymes, including
glutathione S-transferase (GST). A ubiquitous cytosolic
protein, GST catalyzes the conjugation of glutathione to
a variety of substrates, including reactive oxygen species
and other toxins, facilitating their elimination. Four
classes of GST have been identified: a, μ, π and θ.
Approximately one half of all individuals of European
ancestry are homozygous for a deletion at the GST Mu-
1 (GSTM1)l o c u s( GSTM1-null) [11] located on chro-
mosome 1 (1p13.1).
The GSTM1-null genotype has been associated with
an increased risk of RA and in most [12-14] but not all
[15] case control studies. In addition to being implicated
as a potential risk factor in RA, the GSTM1-null geno-
type is associated with higher levels of oxidative stress
[16] and has been reported to be a risk factor for other
smoking-related inflammatory diseases, including
asthma, emphysema and atherosclerosis [17-21]. How-
ever, there have been no studies examining associations
of GSTM1 genotypes with ACPA expression in patients
with RA. This represents an important knowledge gap,
since these antibodies are disease-specific, have signifi-
cant prognostic and pathogenic significance and are
increasingly recognized to characterize a unique subset
of patients with RA [22,23]. In the present study, we
have evaluated potential gene-gene interactions by
exploring the GSTM1-null genotype as a risk factor for
ACPA positivity in RA, providing evidence of an inter-
action with HLA-DRB1 shared epitope (SE)-containing
alleles.
Materials and methods
Study subjects
All study subjects satisfied the American College of
Rheumatology (ACR) criteria for RA [24] and were from
two U.S. cohorts: the Veterans Affairs Rheumatoid
Arthritis (VARA) registry [25] and the Study of New-
Onset Rheumatoid Arthritis (SONORA) [26]. To limit
population heterogeneity, analyses were limited to indi-
viduals self-reporting Caucasian race for whom banked
samples and HLA-DRB1 data were available.
VARA is a multicenter registry with sites at nine VA
medical centers in Brooklyn, NY; Dallas, TX; Denver,
CO; Iowa City, IA; Jackson, MS; Omaha, NE; Portland,
OR; Salt Lake City, UT; and Washington, DC. The reg-
istry has Institutional Review Board approval at each
site, and patients provided informed written consent.
Patients are eligible if they are U.S. Department of
Veterans Affairs (VA) beneficiaries. SONORA includes
patients with recent-onset RA enrolled within 12 months
of diagnosis as part of a 5-year prospective follow-up
study [26]. SONORA patients were recruited from 98
rheumatology practices in the U.S. and Canada, and all
participants provided informed written consent. Vari-
ables abstracted from the corresponding data sets
included age, gender and smoking status (never, former,
or current). Smoking status in both cohorts was
obtained using questionnaires reflecting exposure at the
time of enrollment. Quantitative measures of smoking
(pack-years and duration) were not routinely collected.
Anticitrullinated protein antibody (ACPA)
Serum ACPA (immunoglobulin G (IgG)) was measured
using second-generation enzyme-linked immunosorbent
assays (ELISAs) in VARA (Diastat, Axis-Shield Diagnos-
tics Ltd., Dundee, Scotland, UK; positive ≥5U / m l )a n d
SONORA (Inova Diagnostics, San Diego, CA, USA;
positive ≥20 U/ml) using serum samples collected at
enrollment.
Determination of GSTM1 genotype
Primers “G2” and “G3” from a study by Brockmöller
et al. [27] were used to amplify exons 3 through 5 of
the GSTM1 gene using genomic DNA that was prepared
from whole blood. These primers produce a 650-bp
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Page 2 of 10amplified fragment in individuals carrying at least one
functional GSTM1 allele. This band is absent in
GSTM1-null individuals because this mutation deletes
exons 4 and 5. A 195-bp fragment of exon 7 of the
CYP1a1 gene was used as an internal positive control
for sample quality and polymerase chain reaction (PCR)
using the primers described by Shields et al.[ 2 8 ] .
Amplified products were resolved by electrophoresis
through 1% agarose gels. Genotypes were scored inde-
pendently by two investigators (KAG and KKB). On the
basis of the empiric evidence for associations of this
genotype across multiple conditions [17,29-31], indivi-
duals were categorized as GSTM1-null (homozygous for
deletion) or GSTM1-present (one or two copies of func-
tional allele). Individuals with an absent or faint CYP1a1
band (n =8f r o mV A R Aa n dn = 25 from SONORA)
were excluded from further analyses, leaving available
data from 703 VARA individuals and 610 SONORA
participants for analysis.
Determination of HLA-DRB1 genotypes
In VARA, HLA genotyping was performed using one of
two approaches: DNA sequencing of exon 2 using the
AlleleSEQR HLA-DRB1 reagent kit and protocol (Abbott
Molecular, Abbott Park, IL, USA) or with a PCR-based,
sequence-specific oligonucleotide probe system. In the
second of these methods, a series of oligonucleotide
probes corresponding to known sequence motifs in HLA-
DRB1 were immobilized onto a backed nylon membrane
to create a “linear array.” Exon 2 of DRB1 was amplified
with a set of upstream biotinylated PCR primers corre-
sponding to known sequence motifs in the first variable
region of DRB1 and a single downstream biotinylated PCR
primer that amplifies all alleles. This method specifically
amplified only DRB1 genes and avoided amplification of
other DRB genes. The PCR product was denatured and
hybridized to the 81-probe DRB1 linear array. Arrays were
incubated with streptavidin-horseradish peroxidase fol-
lowed by tetramethylbenzidine. Images were created by
placing the arrays on a flatbed scanner, and probe intensi-
ties were measured with proprietary software. Preliminary
genotypes were determined, and data were then imported
into Sequence Compilation and Rearrangement Evaluation
software (SCORE(tm), QIAGEN, Valencia, CA, USA) for
final genotyping and data export. The following were con-
sidered to be DRB1 shared epitope (SE)-containing alleles:
*0101, *0102, *0104, *0105, *0401, *0404, *0405, *0408,
*0409, *1001, *1402 and *1406.
In SONORA, all participants were HLA-DRB1-typed
as previously described [32] initially using the sequence-
specific oligonucleotide probes (SSOP) low-resolution
method [33]. Individuals with DRB1 *04 and *01 were
subsequently tested using a medium-resolution panel to
allow for four-digit DRB1 subtyping.
Statistical analyses
Associations of the GSTM1-null genotype with ACPA
positivity were examined for each RA cohort using mul-
tivariate unconditional logistic regression. All analyses
were adjusted for age (continuous variable) and gender
to facilitate comparisons across the two divergent
patient cohorts that differed based on these factors.
Associations of HLA-DRB1 SE (positive vs. negative in
addition to the number of SE alleles, 0 vs. 1 or 2) and
smoking status modeled as ever versus never (and as
current or former vs. never in a separate model) with
ACPA positivity were also examined in separate ana-
lyses. Patients were then categorized on the basis of the
presence of risk factor pairings (GSTM1-SE, GSTM1-
smoking and smoking-SE), and associations of these risk
factor assignments with outcomes were examined using
similar regression techniques.
Gene-gene (GSTM1-SE) and gene-environment
(GSTM1-smoking and SE-smoking) interactions were
assessed with regard to ACPA positivity by examining
for evidence of departure from additivity using the
methods described by Rothman et al.[ 3 4 ] .T h r e e - w a y
interactions were not examined. Using this approach,
an attributable proportion (AP) due to interaction (AP
= 0 corresponds to no interaction, and AP = 1.0 corre-
sponds to “complete” additive interaction) and 95%
confidence intervals (CIs) were calculated, using the
method of Hosmer and Lemeshow [35] to calculate
the latter. The confidence interval serves as a statistical
test of the interaction; if the null value (zero in this
case) falls outside the interval, then the interaction is
considered statistically significant. This method
accounts for both the random variability and overlap-
ping intervals in strata defined by the risk factors of
interest [35]. Evidence of multiplicative interaction was
examined by modeling the product term of interest.
To optimize study power, assessments of interaction
were limited to dichotomous variables (SE-positive vs.
SE-negative, ever vs. never smoking) and to two-way
interactions. All analyses were conducted using Stata
version 10.0 software (Stata Corp., College Station,
TX, USA).
Results
Patient characteristics
Patient characteristics are summarized in Table 1. Con-
sistent with the demographic characteristics of VA bene-
ficiaries nationally [36], VARA registry patients were
predominantly men (93%) with a mean (± SD) age of 64
(± 11) years. In contrast, SONORA patients were
younger, with a mean (SD) age of 53 (± 15) years, and
were predominantly women (72%). A majority of
patients were seropositive for ACPA (76% in VARA
Registry and 69% in SONORA).
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The frequency of RA-related risk factors is shown in
Table 1. The prevalence of at least one HLA-DRB1 SE-
containing allele was similar in the VARA Registry
( 7 6 % )a n dS O N O R A( 7 1 % )( P = NS). Approximately
one half of patients (53% in the VARA Registry and
52% in SONORA) were GSTM1-null (P =N S ) ,a n da
majority had a history of smoking, either current or for-
mer (80% in the VARA Registry and 65% in SONORA;
P < 0.05).
Age- and gender-adjusted associations
Associations of GSTM1, smoking, and HLA-DRB1 status
with ACPA positivity in the VARA registry and
SONORA are summarized in Table 2. In reference to
patients with at least one functional GSTM1 allele,
GSTM1-null was associated with a significantly higher
odds ratio (OR) of ACPA positivity in the VARA Regis-
try (OR, 1.45; 95% CI, 1.02 to 2.05), but not in
SONORA (OR, 1.00; 95% CI, 0.71 to 1.42). There was a
significant dose-related association of HLA-DRB1 SE
with ACPA positivity in both cohorts, with more than
10-fold greater odds of ACPA positivity for those with 2
SE alleles compared with those with no SE allele
(Table 2). In both cohorts, there were nonsignificant
trends suggesting associations of current (vs. never)
smoking with ACPA positivity, an effect that appeared
to be more striking in the VARA registry (OR, 1.68;
95% CI, 0.98 to 2.88) than in SONORA (OR, 1.23; 95%
C I ,0 . 7 6t o1 . 9 9 )( T a b l e2 ) .A g e -a n dg e n d e r - a d j u s t e d
associations of composite risk factors with ACPA posi-
tivity are summarized in Table 3.
SE-GSTM1 interactions
In the VARA registry, there was significant additive
interaction between SE and GSTM1 status (AP, 0.46;
95% CI, 0.20 to 0.73; P < 0.001), an interaction that was
evident, albeit of borderline significance, in SONORA
(AP, 0.38; 95% CI, 0.00 to 0.76; P = 0.050). There was
no evidence of a multiplicative SE-GSTM1 interaction in
t h eV A R Ar e g i s t r y( P = 0.25), although the P value of
the product term approached significance in SONORA
(P = 0.06) (Table 3). These results were not changed for
either cohort after further adjustments for cigarette
smoking (Table 3).
In exploratory analyses stratified by SE dose (0, 1 or 2
copies) rather than SE positivity, there were marked dif-
ferences in the associations of composite risk factors of
GSTM1 status and SE dose with ACPA positivity. Com-
pared to individuals lacking both risk factors, SE homo-
zygotes carrying the GSTM1-null genotype were
~28-fold more likely to be ACPA-positive in the VARA
registry (OR, 28.50; 95% CI, 8.21 to 98.87) (Figure 1)
a n d~ 2 1 - f o l dm o r el i k e l yt ob eA C P A - p o s i t i v ei n
SONORA (OR, 21.04; 95% CI, 4.82 to 91.75) (Figure 2).
GSTM1-smoking and SE-smoking interactions
There were no significant additive or multiplicative
interactions between GSTM1 status and smoking for
ACPA positivity in either cohort (Table 3). In contrast,
there was a significant additive interaction between SE
positivity and ever smoking in the VARA registry,
accounting for more than 50% of the overall risk of
ACPA positivity in SE-positive smokers (AP, 0.58; 95%
CI, 0.31 to 0.85; P < 0.001); there was also a nonsignifi-
cant trend to suggest multiplicative interaction (P =
0.054). Consistent with prior reports in SONORA [37],
we observed no evidence of additive or multiplicative
interactions between SE and ever smoking referent to
ACPA positivity in this cohort. To explore the effect of
smoking categorization on this finding, these analyses
were repeated to examine for evidence of interaction
between SE and current smoking (vs. never and former
smoking combined). In these analyses, there was signifi-
cant additive interaction between SE and current smok-
ing (AP, 0.47; 95% CI, 0.13 to 0.82; P =0 . 0 0 8 ) ,b u tn o
evidence of multiplicative interaction (P = 0.153) (data
not shown).
Discussion
Associations of glutathione S-transferase polymorphisms
with RA have been the subject of several other
Table 1 Characteristics of rheumatoid arthritis study
patients
a
Mean (SD) or number (%)
VARA
(n = 703)
SONORA
(n = 610)
Sociodemographics
Age, yr
b 64 (11) 53 (15)
Male gender
b 655 (93%) 173 (28%)
ACPA-positive
b 536 (76%) 420 (69%)
RA risk factors
HLA-DRB1 SE-positive 531 (76%) 434 (71%)
One copy 356 (51%) 303 (50%)
Two copies 175 (25%) 131 (21%)
GSTM1-null 372 (53%) 315 (52%)
Smoking history
b (n = 693) (n = 610)
Never 140 (20%) 213 (35%)
Former 371 (54%) 257 (42%)
Current 182 (26%) 141 (23%)
aACPA, anticitrullinated protein antibody; GSTM1, glutathione S-transferase
Mu-1; SE, shared epitope; SONORA, Study of New-Onset RA; VARA, Veterans
Affairs Rheumatoid Arthritis Registry.
bP < 0.05 for differences between VARA
and SONORA.
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Page 4 of 10Table 2 Association of GSTM1-null, HLA-DRB1 shared epitope (SE) and smoking with ACPA positivity in rheumatoid
arthritis
a
VARA (n = 703) SONORA (n = 610)
ACPA+
(%)
OR (95% CI) P value ACPA+
(%)
OR (95% CI) P value
GSTM1-present 73 Ref.- 6 9 Ref.-
GSTM1-null 79 1.45 (1.02 to 2.05) 0.039 69 1.00 (0.71 to 1.42) 0.981
Never smoking 69 Ref.- 6 9 Ref.-
Ever smoking 78 1.48 (0.97 to 2.26) 0.067 68 0.90 (0.62 to 1.30) 0.574
Former smoking 77 1.41 (0.91 to 2.19) 0.129 65 0.77 (0.52 to 1.14) 0.193
Current smoking 81 1.68 (0.98 to 2.88) 0.059 74 1.23 (0.76 to 1.99) 0.407
SE-negative 53 Ref.- 5 4 Ref.-
SE-positive (one or two alleles) 84 4.36 (2.98 to 6.37) < 0.001 75 2.56 (1.77 to 3.70) < 0.001
SE-positive (one allele) 79 3.23 (2.17 to 4.81) < 0.001 68 1.77 (1.21 to 2.60) 0.003
SE-positive (two alleles) 93 10.65 (5.61 to 20.20) < 0.001 92 10.27 (5.05 to 20.89) < 0.001
aACPA, anticitrullinated protein antibody; CI, confidence interval; GSTM1, glutathione S-transferase Mu-1; OR, odds ratio; SE, shared epitope; SONORA, Study of New-
Onset Rheumatoid Arthritis; VARA, Veterans Affairs Rheumatoid Arthritis Registry. All analyses are age- and gender-adjusted. “Ref.” = referent group in each
analysis.
Table 3 Associations of composite risk factors with ACPA positivity in patients with rheumatoid arthritis
a
VARA (n = 703) SONORA (n = 610)
ACPA+
(%)
OR (95% CI) P value ACPA+
(%)
OR (95% CI) P value
GSTM1/SE
a,b
Present/Negative 50 Ref.- 5 9 Ref.-
Null/Negative 56 1.26 (0.68 to 2.33) 0.456 48 0.63 (0.35 to 1.15) 0.135
Present/Positive 79 3.65 (2.09 to 6.40) < 0.001 72 1.79 (1.05 to 3.03) 0.032
Null/Positive 88 7.30 (4.01 to 13.29) < 0.001 77 2.29 (1.34 to 3.90) 0.002
AP = 0.46 (0.20 to 0.73) AP = 0.38 (0.00 to 0.76)
Padd < 0.001 Padd = 0.050
Pmult = 0.246 Pmult = 0.063
GSTM1/Smoking
a
Present/Never 67 Ref.- 7 2 Ref.-
Present/Ever 75 1.42 (0.80 to 2.52) 0.227 67 0.72 (0.42 to 1.22) 0.223
Null/Never 72 1.35 (0.65 to 2.79) 0.421 67 0.75 (0.42 to 1.36) 0.349
Null/Ever 81 2.01 (1.13 to 3.55) 0.017 70 0.83 (0.49 to 1.42) 0.502
AP = 0.12 (-1.41 to 1.65) AP = 0.44 (-0.28 to 1.15)
Padd = 0.881 Padd = 0.231
Pmult = 0.917 Pmult = 0.245
SE/Smoking
a
Negative/Never 55 Ref.- 5 8 Ref.-
Negative/Ever 53 0.90 (0.40 to 1.99) 0.788 51 0.73 (0.39 to 1.37) 0.329
Positive/Never 73 2.24 (0.97 to 5.16) 0.058 74 2.03 (1.08 to 3.82) 0.027
Positive/Ever 87 5.05 (2.31 to 11.05) < 0.001 75 2.10 (1.17 to 3.78) 0.013
AP = 0.58 (0.31 to 0.85) AP = 0.16 (-0.34 to 0.66)
Padd < 0.001 Padd = 0.530
Pmult = 0.054 Pmult = 0.380
aACPA, anticitrullinated protein antibody; AP, attributable proportion; GSTM1, glutathione S-transferase Mu-1; SE, shared epitope; SONORA, Study of New-Onset
Rheumatoid Arthritis; VARA, Veterans Affairs Rheumatoid Arthritis. All analyses are age- and gender-adjusted.
bCorresponding ORs and 95% for GSTM1/SE
composite risk after further adjustment for ever smoking in VARA: Null/Negative OR = 1.22 (0.66 to 2.27); Present/Positive OR = 3.75 (2.13 to 6.59); Null/Positive
OR = 7.34 (4.02 to 13.34); in SONORA, Null/Negative OR = 0.65 (0.36 to 1.18); Present/Positive OR = 1.80 (1.06 to 3.06); Null/Positive OR = 2.31 (1.36 to 3.95). “Ref.”
= referent group in each analysis.
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Page 5 of 10investigations [12-15,38,39], although none of these have
examined the association of GSTM1 status with ACPA-
positive disease. This study is the first to show that the
GSTM1-null genotype, present in approximately one
half of all individuals of European ancestry, shows a sig-
nificant biologic interaction with HLA-DRB1 SE-contain-
ing alleles with reference to the risk of ACPA positivity
in RA. This is noteworthy, given the disease specificity
(> 95%) of ACPA and the association of worse long-
term outcomes in RA with ACPA seropositivity [22,23].
These results show that patients with both genetic risk
factors (HLA-DRB1 SE and GSTM1-null)a r et w ot o
seven times more likely to be ACPA-positive than
patients lacking both risk factors. Furthermore, ~40% to
50% of the “excess” risk in this group is directly attribu-
table to gene-gene interaction, an interaction that
appears to be independent of smoking status. It is
important to note that the magnitude of this interaction
is similar to that previously reported to exist between
HLA-DRB1 SE positivity and smoking [2,3]. The poten-
tial generalizability of these findings is further bolstered
by its replication in two widely divergent RA cohorts:
one composed primarily of men with long-standing dis-
ease and the other including primarily women with
early-onset disease. These data are an important addi-
tion to studies showing significant additive interactions
Figure 1 Age- and gender-adjusted associations of composite HLA-DRB1 SE dose (0, 1 or 2 alleles) and glutathione S-transferase Mu-1
(GSTM1) status with anticitrullinated protein antibody (ACPA) positivity in Caucasian patients enrolled in the Veterans Affairs
Rheumatoid Arthritis (VARA) registry (n = 703).
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positive RA [2,3]. Our results support the hypothesis
that an oxidative environment promoted through the
absence of functional GSTM1 enzyme potently enhances
the risk of ACPA positivity in RA conferred by the pre-
sence of HLA-DRB1 SE.
Oxidative stress plays a pathogenic role in other auto-
immune and inflammatory conditions, including sys-
temic lupus erythematosus (SLE), scleroderma, diabetes
and atherosclerosis [40]. Compared to those with func-
tional GSTM1, individuals with the GSTM1-null geno-
type appear to be more prone to have increased levels
of oxidative stress following exposure to select toxins
[41]. Oxidation of nucleotides by reactive oxygen species
increases the immunogenicity of DNA in SLE, generat-
ing autoantigens with significantly higher affinity for cir-
culating autoantibodies [42]. In addition to modifying
DNA and lipids, oxidative stress promotes the formation
of neoantigens through posttranslational peptide modifi-
cation. Bang et al. [43] have shown that oxidation of
citrullinated vimentin, implicated as an autoantigen in
RA, leads to substantially increased antibody reactivity
to this antigen in RA.
Our results complement the prior findings of
Klareskog et al. [2], who reported that patients who had
ever smoked and were homozygous for SE were 21
times more likely to develop ACPA-positive RA com-
pared to SE-negative patients who had never smoked.
Results from the Swedish case control study [2] differed
from an analysis of three North American cohorts
including SONORA [37], which found no evidence of
interaction between SE and ever smoking in SONORA
and only weak evidence of interaction in one of the two
other cohorts examined. In these two other cohorts, but
not in SONORA, ever smoking showed a borderline
association with ACPA positivity with ORs approaching
Figure 2 Age- and gender-adjusted associations of composite HLA-DRB1 SE dose (0, 1 or 2 alleles) and GSTM1 status with ACPA
positivity in Caucasian patients enrolled in SONORA (n = 610).
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Page 7 of 101.4 [37]. Although it was not statistically significant, we
found a similar association of ever smoking with ACPA
positivity in the VARA registry with an OR of 1.48, sug-
gesting that our study was underpowered to detect this
association because of the relatively small proportion of
never smokers in the VARA Registry.
Differences in these reports (and differences between
the VARA registry and SONORA) could relate to popu-
lation heterogeneity, including differences in gender dis-
tribution and cumulative smoking exposure. Compared
to women, men have been shown to have a higher pene-
trance of HLA-DRB1 [44], are more likely to smoke and
( a m o n gs m o k e r s )a r em o r el i k e l yt ob ec a t e g o r i z e da s
heavy smokers [45]. Differences in smoking exposure
may be salient here, given findings from a separate
North American study showing that SE-smoking inter-
actions in the risk of seropositive RA (a combined rheu-
matoid factor (RF)/ACPA-positive phenotype) were
limited to individuals with heavy smoking (> 10 pack-
years) [46]. The importance of quantifying cumulative
smoking exposure has also recently been shown among
African Americans with RA risk limited to those with
more than 10 pack-years of exposure [47]. Cumulative
smoking exposure was not available in the present study
involving the VARA registry and SONORA, precluding
such analyses. Underscoring the potential importance of
accounting for cumulative exposure, we observed signifi-
cant SE-smoking interactions in SONORA when smok-
ing exposure was dichotomized as current vs.
noncurrent rather than ever vs. never, with the “current”
category likely to account for individuals with greater
lifelong smoking exposure.
These results differ from a prior study showing signifi-
cant multiplicative interactions between GSTM1-null
status and smoking in RA disease risk [12], an effort
that did not include examinations of GSTM1-SE interac-
tions. In the present study, we found no evidence of sig-
nificant interaction (multiplicative or additive) between
GSTM1-null and smoking in ACPA positivity, a pheno-
type that was not examined in the prior nested case
control analysis from the Iowa Women’s Health Study
[12]. It is possible that in the present study we simply
lacked sufficient power to detect this interaction. Differ-
ences in study design (case only vs. case control) and
study populations (smoking prevalence and predomi-
nantly male vs. female patients) may also help explain
these discrepant study results.
Controversy and uncertainty remain regarding the
most appropriate manner in which to model gene-gene
and gene-environment interactions [48]. In contrast to
prior studies that have examined smoking-SE interactions
in RA risk by calculating only measures of additive inter-
action [2,49], we have examined measures of both addi-
tive and multiplicative interaction. Multiplicative
interaction refers to the inclusion of a product term in
regression analyses to generate an optimal fit of the data
in the statistical model. It is important to note that the
absence of multiplicative interaction does not exclude the
existence of important biologic interactions. For example,
the present study shows that at least one pathway to
ACPA positivity in RA requires the presence of two risk
factors (that is, GSTM1-null and HLA-DRB1 SE).
Although they involved two large independent
cohorts, our analyses were limited to two-way interac-
tions. We lacked the sample sizes even after combining
cohorts that would be necessary to examine more com-
plex interactions, including analyses of GSTM1-SE stra-
tified by smoking status. Future analyses of this sort
with larger patient populations will be essential not only
in replicating our findings but also in providing critical
insight into mechanisms underpinning these observed
interactions. Although this study included a case-only
approach, ACPA positivity is increasingly recognized as
a distinct disease phenotype in RA. Indeed, the well-
defined associations of cigarette smoking and HLA-
DRB1 SE with RA in European populations apply only
to ACPA-positive disease and do not apply to seronega-
tive disease [2]. Because of the limited sample sizes in
subgroups of interest, our study did not include analyses
of interactions of distinct HLA-DRB1 subtypes with
GSTM1. Recent findings have shown that different *01
and *04 subtypes appear to contribute equally to SE-
smoking interactions in ACPA-positive RA [50], sug-
gesting that analyses of specific SE subtypes may yield
limited incremental information.
Conclusions
The GSTM1-null genotype, observed in approximately
50% of individuals of European ancestry, shows signifi-
cant interactions with HLA-DRB1 SE alleles in ACPA
positivity among patients with RA. Future studies will
be needed to explore precisely how GSTM1 and other
antioxidant enzymes influence disease expression in RA.
Along with other recent reports, this work emphasizes
the need for the simultaneous investigation of multiple
genetic and environmental factors to better understand
the pathogenic contributions of these elements to the
development and progression of RA with potential
application to other autoimmune diseases.
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